SCHEMBL5535847

SCHEMBL5535847

[c]1nc2ccc(-c3ccccc3)cc2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.50
PI4KA P42356 1/20 0.50
PI4KB Q9UBF8 1/20 0.50
PIK3CG P48736 2/20 0.41
BACE1 P56817 1/20 0.41
ABL1 P00519 2/20 0.40
MAP4K4 O95819 2/20 0.39
ALOX5 P09917 1/20 0.36
TRIM58 Q8NG06 1/20 0.36
PIK3R1 P27986 1/20 0.36
LIMK1 P53667 1/20 0.36
ROCK2 O75116 1/20 0.35
PRKCG P05129 1/20 0.35
LYN P07948 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35
AKT1 P31749 1/20 0.35
FLT3 P36888 1/20 0.35
CSNK1D P48730 1/20 0.35
CLK2 P49760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541045 0.85 PIK3CA (0.42) PIK3CAPI4KAPI4KBPIK3CGBACE1
SCHEMBL5540744 0.81 ABL1 (0.44) ABL1MAP4K4LIMK1DYRK1AL3MBTL1
SCHEMBL448177 0.74
SCHEMBL6067699 0.74 NPC1 (0.39) CSNK1DGAAL3MBTL1ALDH1A1
SCHEMBL3484 0.74
SCHEMBL3144534 0.72 NQO2 (0.43) PI4KAPI4KBL3MBTL1ALDH1A1
SCHEMBL206753 0.72 GFER (0.44) BACE1DYRK1AALDH1A1
SCHEMBL206103 0.72 SMN1; SMN2 (0.41) PIK3CGDYRK1AGAAALDH1A1
SCHEMBL212513 0.72 MAPT (0.44) BACE1DYRK1AGAAL3MBTL1ALDH1A1
SCHEMBL6601753 0.72 HTT (0.44) DYRK1AGAAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PIK3CA 4371/4885PI4KA 3992/4885PI4KB 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.